Summary
This Alnylam Pharmaceuticals 10-Q filing for the period ending June 30, 2019, highlights significant progress in commercializing ONPATTRO and advancing its pipeline, alongside substantial ongoing investment in research and development. The company reported a 50% increase in total revenues year-over-year, primarily driven by the launch of ONPATTRO, which generated $38.2 million in the second quarter and $64.5 million in the first half of the year. Despite this revenue growth, Alnylam continues to incur significant operating losses, with a net loss of $219.5 million for the quarter and $401.4 million for the first half, reflecting its heavy investment in R&D to support its "Alnylam 2020" strategy. A key development highlighted is the strong financial footing provided by a $400 million upfront payment and equity investment from Regeneron in May 2019, supplementing a $381.9 million net proceeds from a public offering in January 2019. These capital infusions, combined with existing cash reserves, are expected to fund operations for multiple years. The company is advancing several late-stage investigational programs, including givosiran for acute hepatic porphyria (AHP), which has received Priority Review from the FDA with a PDUFA date set for February 4, 2020. Investors should note the continued substantial R&D spending, the reliance on strategic partnerships, and the inherent risks associated with drug development and commercialization, as emphasized in the risk factors section.
Financial Highlights
46 data points| Revenue | $44.71M |
| Cost of Revenue | $4.33M |
| Gross Profit | $40.39M |
| R&D Expenses | $163.89M |
| SG&A Expenses | $112.77M |
| Operating Expenses | $280.99M |
| Operating Income | -$236.27M |
| Interest Expense | $0 |
| Net Income | -$219.48M |
| EPS (Basic) | $-2.02 |
| Shares Outstanding (Basic) | 108.58M |
Key Highlights
- 1ONPATTRO generated $38.2 million in net product revenues in Q2 2019 and $64.5 million in the first half of 2019, indicating successful commercialization post-2018 launch.
- 2Givosiran, a key pipeline asset for AHP, received Priority Review from the FDA with a PDUFA action date of February 4, 2020, signaling potential near-term approval.
- 3The company bolstered its cash position significantly through a $400 million upfront payment from Regeneron and a $381.9 million public offering in January 2019.
- 4Total revenues increased by 50% year-over-year to $44.7 million in Q2 2019 and $78.0 million in the first half, largely due to ONPATTRO sales.
- 5Research and development expenses increased by 19% in Q2 2019 to $163.9 million, reflecting continued investment in pipeline advancement, including license fees related to the Regeneron collaboration.
- 6Selling, general, and administrative expenses rose by 33% in Q2 2019 to $112.8 million, driven by commercialization efforts for ONPATTRO and expansion of global operations.
- 7Despite revenue growth, the company incurred substantial net losses ($219.5 million in Q2, $401.4 million YTD), consistent with its strategy of heavy R&D investment.